Patrick Flaherty, DO
Cardiovascular Disease · Little Rock, ARNPI 1740273184
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,429 of the $4,643 with a category attached, or 73.9%. Abbott accounts for 62.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $2,260 and has fallen 92.0% since, to $182 in 2025.
Across 93 payments — averaging $49.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Shockwave Medical, Inc$452
- Novartis$325
- Johnson & Johnson$276
- Opsens Inc.$180
- Biotronik Inc.$130
- plus $358 from 10 others
What the payments were for
- Travel & lodging$1,21426%
- Food & beverage$3,42974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $2,922 |
| Shockwave Medical, Inc | 3 | $452 |
| Novartis | 25 | $325 |
| Johnson & Johnson | 16 | $276 |
| Opsens Inc. | 2 | $180 |
| Biotronik Inc. | 1 | $130 |
| Boston Scientific | 2 | $120 |
| AstraZeneca | 5 | $70 |
| Novo Nordisk | 3 | $50 |
| Inari Medical, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Cordis US CORP. | 1 | $16 |
| Merck | 1 | $14 |
| Amgen | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,643 in reported general payments places this provider in the 55th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 482 | $329,419 |
| FarxigaDapagliflozin Propanediol | 310 | $227,449 |
| EntrestoSacubitril/Valsartan | 121 | $97,115 |
| XareltoRivaroxaban | 66 | $67,093 |
| MultaqDronedarone Hcl | 45 | $46,354 |
| OzempicSemaglutide | 38 | $46,237 |
| JardianceEmpagliflozin | 48 | $45,819 |
| Repatha SureclickEvolocumab | 57 | $34,045 |
| MounjaroTirzepatide | 24 | $24,543 |
| BrilintaTicagrelor | 41 | $20,553 |
| Praluent PenAlirocumab | 37 | $17,932 |
| ClopidogrelClopidogrel Bisulfate | 747 | $6,087 |
| Metoprolol Succinate | 537 | $5,104 |
| Atorvastatin Calcium | 365 | $3,039 |
| Rosuvastatin Calcium | 452 | $2,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $70 | $248,002351 claims |
| NovartisEntresto | $325 | $97,115121 claims |
| Johnson & JohnsonXarelto | $276 | $67,09366 claims |
| Novo NordiskOzempic | $50 | $46,23738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.